Key result
Combined detection of serum CTRP9 and STIM1 levels predicted restenosis after cerebrovascular stent implantation with a sensitivity of 90.32%, specificity of 48.48%, and an AUC of 0.747.
Why the study?
The study investigated the predictive value of serum CTRP9 and STIM1 for restenosis after cerebrovascular stent implantation, alongside their relationship with vasoactive substances and inflammatory cytokines.
Do serum CTRP9 and STIM1 levels predict restenosis after cerebrovascular stent implantation in patients with cerebral infarction?
Observational (n=128)
No
Do serum CTRP9 and STIM1 levels predict restenosis after cerebrovascular stent implantation in patients with cerebral infarction?
Decreased serum CTRP9 and increased STIM1 levels are associated with restenosis after cerebrovascular stent implantation and may serve as predictive biological indicators.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for restenosis biomarkers post-stenting; leaves open prospective validation before clinical use.
Predictive value of serum complement Clq tumor necrosis factor-related protein 9 (CTRP9) and serum stromal interaction molecule 1 (STIM1) was investigated for restenosis after cerebrovascular stent implantation, as well as its relationship with vasoactive substances and inflammatory cytokines. In this prospective study, 128 patients with cerebral infarction treated with cerebrovascular stent implantation in Yantaishan Hospital were recruited. A total of 66 cases with restenosis after cerebrovascular stent implantation were included in group A, and 62 cases without stenosis were included in group B. Serum CTRP9 and STIM1 levels were measured by enzyme-linked immunosorbent assay (ELISA). ROC curves of serum CTRP9 and STIM1 levels in patients with postoperative restenosis were drawn. The vasoactive substances nitric oxide (NO), tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) were analyzed by ELISA. The correlation of serum CTRP9, STIM1 levels and NO, TNF-α, IL-6 were analyzed by Pearson correlation coefficient. Serum CTRP9 and NO levels in group A were significantly lower than those in group B. The levels of serum STIM1, TNF-α and IL-6 in group A were significantly higher than those in group B (P<0.001). The sensitivity and specificity of serum CTRP9 level in the diagnosis of restenosis after cerebrovascular stent implantation were, respectively, 59.68 and 75.76%. Those of serum STIM1 were, respectively, 87.10 and 46.97% and those of the combination of serum CTRP9 and STIM1 were 90.32 and 48.48%. Serum CTRP9 level was positively correlated with NO, and negatively correlated with TNF-α and IL-6. STIM1 was positively correlated with TNF-α and IL-6, and negatively correlated with NO (P<0.001). Serum CTRP9 level was significantly decreased in patients with restenosis after cerebrovascular stent implantation, while STIM1 level was significantly up-regulated. Both were correlated with the change of NO, IL-6 and TNF-α levels, therefore they could be used as biological indicators for prediction of restenosis after cerebrovascular stent implantation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2020) conducted an observational in Restenosis after cerebrovascular stent implantation (n=128). Serum CTRP9 and STIM1 levels vs. Patients without restenosis was evaluated on Restenosis after cerebrovascular stent implantation (AUC 0.747, p=<0.001). Combined detection of serum CTRP9 and STIM1 levels predicted restenosis after cerebrovascular stent implantation with a sensitivity of 90.32%, specificity of 48.48%, and an AUC of 0.747.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: